Kelun-Biotech's SKB445 ADC Receives NMPA Approval for Advanced Solid Tumor Trials
Kelun-Biotech's SKB445, a novel antibody-drug conjugate (ADC), has been approved by China's NMPA for clinical trials in advanced solid tumors.
© Copyright 2025. All Rights Reserved by MedPath